
Keywords: systemic juvenile arthritis; CRP; C-reactive protein; FDA; US Food and Drug Administration; IL; Interleukin; ILAR; International League of Associations for Rheumatology; JIA; Juvenile idiopathic arthritis; MAS; Macrophage activation syndrome; SJIA; System